» Articles » PMID: 9950792

Effects of Sex Steroid Hormones on Regional Fat Depots As Assessed by Magnetic Resonance Imaging in Transsexuals

Overview
Journal Am J Physiol
Specialty Physiology
Date 1999 Feb 10
PMID 9950792
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated prospectively the effect of sex steroids on regional fat depots and thigh muscle mass in adult transsexuals. Ethinyl estradiol in combination with cyproterone acetate, a progestational antiandrogen, was given to 20 male-to-female (M-F) transsexuals, and parenteral testosterone esters were given to 17 female-to-male (F-M) transsexuals. Before and after 12 mo of cross-sex hormone administration, several anthropometric measurements (weight, skinfolds, body circumferences, and bioimpedance) were performed, and transverse magnetic resonance images were obtained at the level of the abdomen, hip, and thigh to quantify fat depots (subcutaneous and visceral) and muscle areas. We observed that treatment with ethinyl estradiol in M-F transsexuals induced a significant increase in all subcutaneous fat depots, with a lesser but proportional and significant increase in the visceral fat depot and a decrease in thigh muscle area. Testosterone administration in F-M transsexuals markedly increased thigh muscle area, reduced subcutaneous fat deposition at all levels measured, but slightly increased the visceral fat area. We conclude that sex steroid hormones are important determinants of the sex-specific localization of body fat.

Citing Articles

The effects of gender-affirming hormone therapy on myocardial, hepatic, pancreatic lipid content, body fat distribution and other cardiometabolic risk factors: A magnetic resonance-based study in transgender individuals.

Slukova D, Deischinger C, Just I, Kaufmann U, Trattnig S, Krssak M J Clin Transl Endocrinol. 2025; 39:100379.

PMID: 39758096 PMC: 11696847. DOI: 10.1016/j.jcte.2024.100379.


Metabolic Features of Assigned Female at Birth Transgender People on Gender-Affirming Hormone Therapy: A Meta-analysis.

Tienforti D, Castellini C, Di Giulio F, Spagnolo L, Muselli M, Fisher A Transgend Health. 2024; 9(6):466-483.

PMID: 39735373 PMC: 11669637. DOI: 10.1089/trgh.2023.0040.


Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function.

McGinley K, Lucas-Herald A, Connelly P, Delles C Endocr Connect. 2024; .

PMID: 39585765 PMC: 11728916. DOI: 10.1530/EC-24-0222.


Adipokine secretion and lipolysis following gender-affirming treatment in transgender individuals.

Subramanian N, Wiik A, Rullman E, Melin M, Lundberg T, Flanagan J J Endocrinol Invest. 2024; 47(9):2249-2260.

PMID: 38460092 PMC: 11368987. DOI: 10.1007/s40618-024-02323-4.


In vivo techniques for assessment of insulin sensitivity and glucose metabolism.

Hahn M, Giacca A, Pereira S J Endocrinol. 2024; 260(3).

PMID: 38198372 PMC: 10895285. DOI: 10.1530/JOE-23-0308.